FDA approves new oral drug for overactive bladder

Trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria